

## Australia's CSL inks global research agreements to fast-track therapeutics innovation

06 October 2023 | News

**CSL's Global Research Acceleration Initiative freshly inks promising research partnerships in Europe and, for the first time, Asia and the UK**

Australian behemoth CSL's Research Acceleration Initiative (RAI) continues to expand its reach with seven medical researchers awarded new RAI partnerships, including up to an AU\$500,000 investment in each programme over two years, to fast-track the discovery of innovative biotherapies to address unmet medical needs.

The CSL Research Acceleration Initiative establishes partnerships between CSL and global research organisations to progress discoveries towards real-world treatments and accelerate the commercialisation of promising discovery programmes.

**Dr Laurent Martinez at Institute of Cardiovascular and Metabolic Diseases (I2MC), IHU HealthAge, INSERM / University of Toulouse, France,** is developing a novel class of therapeutic candidates for vascular diseases including stroke. I

**Prof. Delphine Borgel, at INSERM - APHP - Université Paris SACLAY, France** is developing therapeutic nanobodies for the prevention and treatment of vaso-occlusive crisis in sickle cell disease without increased risk of infections.

**Prof. Denis Vivien, at INSERM / Caen Normandie University Hospital, France** aims to establish improvements in diagnosis and treatment of neurovascular diseases by targeting micro-thrombi with nanoparticles that are safe and do not induce hemorrhagic transformation.

**Research Director Benoit Salomon, at INSERM / University of Toulouse, France** intends to stimulate regulatory T cells for the treatment of autoimmune myositis and increased muscle regeneration after injury.

**Assoc Prof. Tan Meng How, Nanyang Technological University, Singapore** will research novel methods, utilising DNA repair proteins, to enhance insertional gene editing in human cells.

**Prof. Elisa Laurenti, at University of Cambridge, United Kingdom** will investigate mRNA-based solutions to minimise the loss of haematopoietic stem cell (HSC) function occurring during an ex vivo gene therapy protocol.

**Prof. Leon Schulte, at Philipps-Universität Marburg, Germany** will investigate the targeting of long non-coding RNAs (lncRNA) to enable precision-interventions in misguided immune-circuits during systemic inflammatory response-syndrome (SIRS), thus aiming to improve the survival rate of affected patients.